VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Racotumomab Vaccine
Vaccine Information
  • Vaccine Name: Racotumomab Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007083
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • KRAS gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • NRAS gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • HRAS gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: Racotumomab is adjuvanted with aluminum hydroxide for intradermal administration as a cancer vaccine (Gajdosik, 2014).
  • Description: This is for Lung Cancer (NCT01598454). An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells (Gabri et al., 2016; NCIT_C95024).
Host Response
References
Gabri et al., 2016: Gabri MR, Cacciavillano W, Chantada GL, Alonso DF. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert opinion on biological therapy. 2016; 16(4); 573-578. [PubMed: 26903265].
Gajdosik, 2014: Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs of today (Barcelona, Spain : 1998). 2014; 50(4); 301-307. [PubMed: 24918647].
NCIT_C95024: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95024]
NCT01598454: [https://clinicaltrials.gov/ct2/show/NCT01598454]